

[Meglumine antimoniate](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.2. Antileishmaniasis medicines](#)

ATC codes: [P01CB01](#)

EMLc

Indication

Cutaneous leishmaniasis ICD11 code: [1F54.1](#)

Medicine type

Chemical agent

List type

Core

Formulations

**Parenteral > General injections > IM:** 1.5 g per 5 mL in 5 mL ampoule

EML status history

First added in 1987 ([TRS 770](#))

Changed in 1989 ([TRS 796](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Meglumine antimoniate](#)

DrugBank

[Meglumine antimoniate \(Pentavalent Antimony\)](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial  
Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule